Arvinas Inc
NASDAQ:ARVN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
21.64
52.31
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ARVN stock under the Base Case scenario is 11.88 USD. Compared to the current market price of 25.86 USD, Arvinas Inc is Overvalued by 54%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Arvinas Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ARVN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Arvinas Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Arvinas Inc
Balance Sheet Decomposition
Arvinas Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 1.1B |
Receivables | 14.8m |
Other Current Assets | 13.1m |
Non-Current Assets | 17.6m |
PP&E | 7.8m |
Other Non-Current Assets | 9.8m |
Current Liabilities | 275.9m |
Accounts Payable | 93.6m |
Accrued Liabilities | 54.9m |
Other Current Liabilities | 127.4m |
Non-Current Liabilities | 305.2m |
Long-Term Debt | 600k |
Other Non-Current Liabilities | 304.6m |
Earnings Waterfall
Arvinas Inc
Revenue
|
282.7m
USD
|
Operating Expenses
|
-876.3m
USD
|
Operating Income
|
-593.6m
USD
|
Other Expenses
|
72.5m
USD
|
Net Income
|
-521.1m
USD
|
Free Cash Flow Analysis
Arvinas Inc
USD | |
Free Cash Flow | USD |
ARVN Profitability Score
Profitability Due Diligence
Arvinas Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Arvinas Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
ARVN Solvency Score
Solvency Due Diligence
Arvinas Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Arvinas Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARVN Price Targets Summary
Arvinas Inc
According to Wall Street analysts, the average 1-year price target for ARVN is 64.66 USD with a low forecast of 28.28 USD and a high forecast of 115.5 USD.
Dividends
Current shareholder yield for ARVN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ARVN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 280 full-time employees. The company went IPO on 2018-09-27. The firm is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three lead product candidates are ARV-110, ARV-471 and ARV-766. The company develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). The company develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The company develops ARV-766, a PROTAC protein degrader for the treatment of men with metastatic castration-resistant prostate.
Contact
IPO
Employees
Officers
The intrinsic value of one ARVN stock under the Base Case scenario is 11.88 USD.
Compared to the current market price of 25.86 USD, Arvinas Inc is Overvalued by 54%.